Tag: roxadustat market trends

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Will The Roxadustat Market Valuation Change Between Now And 2029?

The market size of roxadustat has experienced substantial growth in the preceding years. An increase from $6.44 billion in 2024 to $6.86 billion in 2025 is anticipated, at a compound annual growth rate (CAGR) of 6.5%. The expansion witnessed during the historic period is credited to the sanctioning of regulatory approvals in prime markets, positive outcomes from clinical trials, a rising incidence of chronic kidney disease, increased consciousness about the management of anemia, and government backing for treatments of anemia.

In the coming years, the roxadustat market is predicted to witness significant growth, reaching the value of “$8.95 billion by 2029 with a compound annual growth rate (CAGR) of 6.9%. The projected growth for this period is attributed to continuing new indication research, a surge in healthcare spending, the preference for non-injectable anemia treatments, growing favorable reimbursement policies, and an increasing elderly population. Notable trends during the forecast period include shifting towards oral anemia treatments, rising competition from alternative remedies, extending licensing agreements, heightened investment in hypoxia-inducible factor research, and a focus on treatments that prioritize the patient’s needs.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp

Which Growth Drivers Are Shaping The Roxadustat Market Outlook?

The escalating prevalence of people suffering from chronic kidney disease (CKD) is anticipated to fuel the expansion of the Roxadustat market. CKD is a progressive medical condition in which the kidneys lose their effectiveness gradually, often resulting in kidney failure if not addressed timely. The global surge in the numbers of individuals affected by chronic kidney disease can be attributed to aspects like the aging population, amplifying instances of diabetes, hypertension and unhealthy lifestyle habits. Roxadustat plays a crucial role in managing chronic kidney disease by enhancing the secretion of erythropoietin, which escalates the production of red blood cells and tackles anemia that is commonly associated with the disease, resulting in an improvement in kidney functionality and patients’ quality of life. For example, a report issued by the Australian Institute of Health and Welfare (AIHW), a government agency based in Australia, in December 2024, revealed a slight yearly surge in the mortality rates due to chronic kidney disease, registering a growth of 4.2% in 2021 and 6.2% in 2022. Consequently, the increasing prevalence of people with chronic kidney disease (CKD) is propelling the growth of the Roxadustat market.

What Segmentation Insights Are Provided In The Roxadustat Market Research?

The roxadustat market covered in this report is segmented –

1) By Type: 20mg, 50mg

2) By Product Formulation: Oral Tablets

3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers

4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions

Which Notable Trends Are Transforming The Roxadustat Market Outlook?

Major companies operating in the Roxadustat market are opting for reimbursement under the high-tech drugs scheme to ensure broader patient access by reducing financial barriers, thereby accelerating market uptake and demonstrating the cost-effectiveness of their innovative therapies. The high-tech drugs scheme is a government-managed program primarily in Ireland that provides reimbursement for the dispensing of expensive, highly specialized medications typically prescribed in hospital settings. For instance, in September 2022, Astellas Pharma Company Ltd., a US-based pharmaceutical company announced that its EVRENZO (Roxadustat) has been granted reimbursement under the High-Tech Drugs Scheme in Ireland. Roxadustat is the first in a new class of orally administered hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitors licensed and reimbursed in Ireland. The results showed Roxadustat was effective in achieving and maintaining target hemoglobin levels (10-12g/dL) in patients with symptomatic anemia of CKD, regardless of dialysis status and prior ESA treatment.

Which Firms Are Driving Innovation Within The Roxadustat Market?

Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Roxadustat Market?

North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21280&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#How Will the Inhalation CDMO Market Evolve in Terms of Growth and Size by 2029?#_x000D_

The size of the roxadustat market has demonstrated robust growth in the past few years. The market is set to expand from $6.44 billion in 2024 to $6.86 billion in 2025, displaying a compound annual growth rate (CAGR) of 6.5%. The historic period’s growth was driven by factors such as receiving regulatory approvals in significant markets, successful clinical test results, an escalating rate of chronic kidney disease, heightened consciousness regarding anemia management, and governmental backing for anemia treatments._x000D_

_x000D_

The market size for roxadustat is predicted to experience robust expansion over the next couple of years, climbing to a value of “$8.95 billion in 2029 with a compound annual growth rate (CAGR) of 6.9%. This upswing during the forecasted timeframe is linked to continued studies into new usage areas, escalated healthcare spending, the market demand for anemia treatments that don’t involve injections, broadening insurance coverage policies, and an increasing elderly population. The principal trends anticipated in this same period consist of a migration towards oral anemia therapies, intensifying competition from other treatment methods, expanding licensing contracts, rising investment into research around hypoxia-inducible factors, and an emphasis on treatments centred around patients._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp_x000D_

_x000D_

#What factors are expected to fuel Inhalation CDMO market growth in the coming years?#_x000D_

The rise in respiratory disease occurrences is anticipated to stimulate the expansion of the inhalation CDMO market. Respiratory conditions encompass a variety of health issues impacting the respiratory system, including all organs and structures used in breathing. The knowledge and proficiency of inhalation CDMOs in devising and distributing drugs to the lungs make them instrumental in developing and manufacturing treatments for respiratory disorders. This provides pharmaceutical firms with specialized expertise, infrastructure, and resources needed for creating groundbreaking inhalation therapies. For example, the Australian Bureau of Statistics (ABS), a government agency in Australia, reported that 8.5 million Australians, or 34%, suffer from chronic respiratory diseases, which include 2.8 million, or 11%, with asthma, and 638,000, or 2.5% with COPD. The surging prevalence of such respiratory ailments is thus fuelling the growth of the inhalation CDMO market._x000D_

_x000D_

_x000D_

The roxadustat market covered in this report is segmented – _x000D_

_x000D_

1) By Type: 20mg, 50mg_x000D_

2) By Product Formulation: Oral Tablets_x000D_

3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers_x000D_

4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions_x000D_

_x000D_

#What Trends Are Currently Influencing Growth In The Inhalation CDMO Market?#_x000D_

Prominent organizations in the Roxadustat market are pursuing reimbursement through the high-tech drugs scheme. This strategy aims to extend patient reach by diminishing financial constraints, prompting quicker market assimilation and illustrating the cost-effectiveness of their pioneering treatments. The high-tech drugs scheme is a state-operated initiative, chiefly in Ireland, which offers compensation for the provision of costly, highly specialized medicines usually recommended in hospital contexts. For example, in September 2022, the US-based Astellas Pharma Company Ltd. disclosed that its EVRENZO (Roxadustat) has been awarded reimbursement under the High-Tech Drugs Scheme in Ireland. Roxadustat is the inaugural medication of a fresh series of orally ingested hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitors to be licensed and compensated in Ireland. The findings affirmed that Roxadustat was potent in accomplishing and preserving target hemoglobin concentrations (10-12g/dL) in individual suffering symptomatic anemia of CKD, independent of dialysis status and preceding ESA therapy._x000D_

_x000D_

#What Are The Most Active Companies In The Inhalation CDMO Market Today?#_x000D_

Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd. _x000D_

_x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report_x000D_

_x000D_

#Which Regional Markets Are Attracting The Most Investment In Inhalation CDMO?#_x000D_

North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21280&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Are the Projected Market Size and Growth Rates for the Roxadustat Market From 2025 To 2029?#_x000D_

In recent years, the roxadustat market has witnessed robust growth. It is projected to increase from $6.44 billion in 2024 to $6.86 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.5%. This expansion during the historic period is linked to factors such as regulatory authorization in major markets, favorable clinical trial outcomes, a rising incidence of chronic kidney disease, heightened cognizance of anemia management, and governmental backing for anemia therapies._x000D_

_x000D_

The roxadustat market size is forecasted to experience robust growth in the forthcoming years. It’s projected to expand to $8.95 billion in 2029, with a compound annual growth rate (CAGR) of 6.9%. The escalation during this period is expected due to ongoing investigations for new applications, surges in healthcare spending, the need for non-injectable anemia treatments, improved reimbursement options, and an aging population. The significant trends predicted for this period are the move toward oral anemia remedies, mounting competition from substitute treatments, augmentation of licensing accords, increased funding in hypoxia-inducible factor studies, and prioritization of patient-focused therapeutic options._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp_x000D_

_x000D_

#What Are the Primary Drivers Supporting the Market Growth of the Roxadustat Market?#_x000D_

The escalating prevalence of individuals suffering from chronic kidney disease (CKD) is anticipated to catalyze the expansion of the Roxadustat market in the future. CKD characterizes a long-term ailment where kidneys slowly lose their functionality, often escalating to kidney failure if not addressed timely. The global surge in people affected by CKD can be attributed to aging populations, a rise in diabetes and hypertension incidence, and unhealthy living habits. Roxadustat plays a crucial role in managing CKD by triggering the formation of erythropoietin, which boosts the production of red blood cells and mitigates the anemia often linked with the condition, thus enhancing overall kidney functioning and patient quality of life. For instance, a report released by the Australian Institute of Health and Welfare (AIHW), a government agency in Australia, in December 2024 indicated that mortality rates due to CKD witnessed a small annual increase, with a surge of 4.2% in 2021 and 6.2% in 2022. Hence, the escalating prevalence of CKD patients is fuelling the expansion of the Roxadustat market._x000D_

_x000D_

#Which Primary Segments of the Roxadustat Market Are Driving Growth and Industry Transformations?#_x000D_

The roxadustat market covered in this report is segmented – _x000D_

_x000D_

1) By Type: 20mg, 50mg_x000D_

2) By Product Formulation: Oral Tablets_x000D_

3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers_x000D_

4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21280&type=smp_x000D_

_x000D_

#Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Roxadustat Market?# Market?#_x000D_

North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Are the Most Significant Market Trends in the Roxadustat Market?#_x000D_

Prominent firms in the Roxadustat market are resorting to reimbursement through the high-tech drugs scheme, which ensures more extensive patient reach by eliminating financial hurdles, thus promoting market adoption and showcasing the cost-efficiency of their novel treatments. The high-tech drugs scheme, primarily operated by the government in Ireland, offers financial returns for the distribution of costly, highly specialized medicines typically suggested in hospital environments. For instance, in September 2022, US-based Astellas Pharma Company Ltd. declared that its drug EVRENZO (Roxadustat) obtained reimbursement under Ireland’s High-Tech Drugs Scheme. Roxadustat opens a new category of oral hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitors that are licensed and reimbursed in Ireland. The outcomes revealed that Roxadustat was successful in achieving and sustaining target hemoglobin levels (10-12g/dL) in patients with symptomatic anemia of CKD, irrespective of dialysis status and previous ESA treatment._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report_x000D_

_x000D_

#What Parameters Are Used to Define the Roxadustat Market?#_x000D_

Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stabilizes hypoxia-inducible factors, leading to increased erythropoietin production, enhanced iron absorption, and improved hemoglobin synthesis without the need for exogenous erythropoiesis-stimulating agents. It is used to manage anemia by addressing low hemoglobin levels in patients with chronic kidney disease and potentially other conditions involving impaired red blood cell production._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21280_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Roxadustat Market Grown from 2024 to 2025?

The market for Roxadustat has seen significant enlargement in past few years. It is projected to expand from a valuation of $6.44 billion in 2024 to $6.92 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. The historic period’s growth can be linked to numerous factors which includes obtaining regulatory consent in crucial markets, solid outcomes from clinical trials, the rise in cases of chronic kidney disease, increasing enlightenment about anemia management, and governmental backing for anemia therapies.

What Growth Rate Is Anticipated for the Roxadustat Market in the Coming Years?

Predictions suggest a striking growth in the Roxadustat market size over the next few years, expanding to $9.16 billion in 2029 with a compound annual growth rate (CAGR) of 7.3%. Several factors contributing to this growth during the prediction period include continuous exploration for discovering new indicators, escalating expenditure in healthcare, increased preference for non-injectable cures for anemia, broadening reimbursement policies, and an uptick in elderly populations. Key trends expected during this forecasting timeline encompass a transition towards orally administered anemia treatments, increased rivalry from alternative treatment options, broadening of licensing contracts, surge in investments towards research on hypoxia-inducible factor and evolving focus on a more patient-oriented treatment methodology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp

Who Are the Leading Companies in the Roxadustat Market?

Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.

What Are the Key Drivers of the Roxadustat Market?

The increase in individuals suffering from chronic kidney disease (CKD) is anticipated to stimulate the expansion of the Roxadustat market. Chronic kidney disease is a persistent ailment where the kidneys progressively lose their capacity to function adequately, frequently resulting in kidney failure if it’s not taken care of. Factors such as aging society, high diabetes prevalence, high blood pressure, and unhealthy lifestyles contribute to the escalating global count of chronic kidney disease cases. One of the ways Roxadustat contributes to managing CKD is by prompting the production of erythropoietin, which elevates the production of red blood cells and aids in correcting anemia, a common occurrence with this disease. This improves the overall functioning of the kidneys and the quality of life for patients. Taking a specific incident from December 2024 according to the Australian Institute of Health and Welfare (AIHW), a government agency in Australia, there was a mild yearly increase in the mortality rates due to chronic kidney disease, with a rise of 4.2% in 2021 and 6.2% in 2022. Hence, the escalating population of individuals with chronic kidney disease (CKD) is fueling the Roxadustat market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21280&type=smp

What Are the Key Market Segments in the Roxadustat Industry?

The roxadustat market covered in this report is segmented –

1) By Type: 20mg, 50mg

2) By Product Formulation: Oral Tablets

3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers

4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions

Subsegments:

1) By 20mg: Oral Tablets, Injectable Formulations

2) By 50mg: Oral Tablets, Injectable Formulations

What Are the Latest Trends in the Roxadustat Market?

Companies prominent in the Roxadustat marketplace are leveraging the high-tech drugs scheme for reimbursements, aiming to broaden their patient reach by minimizing financial obstacles. This move is boosting market adoption and showcasing the cost-efficiency of their pioneering treatments. The high-tech drugs scheme is predominantly government-controlled, primarily in Ireland, and allows for the payment-back of costly, highly specialized medications that are commonly dispensed in hospital environments. For example, in September 2022, Astellas Pharma Company Ltd., an American pharmaceutical firm, revealed that its EVRENZO (Roxadustat) received reimbursement via the High-Tech Drugs Scheme in Ireland. Roxadustat is the inaugural medication in a new category of orally consumed hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitors that have been licensed and reimbursed in Ireland. The findings indicated that Roxadustat was successful in achieving and sustaining target hemoglobin levels (10-12g/dL) for patients suffering from symptomatic anemia of CKD, irrespective of their dialysis status and previous ESA treatment.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report

What Are the Key Regional Markets in the Roxadustat Industry?

North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21280

This Report Delivers Insight On:

1. How big is the roxadustat market, and how is it changing globally?

2. Who are the major companies in the roxadustat market, and how are they performing?

3. What are the key opportunities and risks in the roxadustat market right now?

4. Which products or customer segments are growing the most in the roxadustat market?

5. What factors are helping or slowing down the growth of the roxadustat market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

#What Is the Current and Projected Market Size of the Roxadustat Market Through 2034?#_x000D_

In recent times, there has been robust growth in the Roxadustat market size. It is projected to expand from $6.44 billion in 2024 to $6.92 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. The growth achieved in the previous period can be credited to regulatory green lights in key markets, impressive results from clinical trials, rising incidence of chronic kidney disease, heightened awareness about managing anemia, and government-backed support for treatments of anemia._x000D_

_x000D_

In the next few years, the Roxadustat market size is projected to witness substantial growth. The prediction is that it will surge to $9.16 billion in 2029 with a compound annual growth rate (CAGR) of 7.3%. Factors such as continuous exploration for new indications, a rise in healthcare spending, the need for non-injectable anemia solutions, widening reimbursement schemes, and the increasing aging population can account for the growth during the forecast period. Significant trends expected in this period involve a shift towards oral anemia treatments, intensifying competition from alternate therapies, expanded licensing contract, heightened investment in hypoxia-inducible factor research, and an emphasis on treatments that prioritize patients._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp_x000D_

_x000D_

#What Are the Core Market Drivers Propelling Growth in the Roxadustat Industry?#_x000D_

The growing prevalence of chronic kidney disease (CKD) worldwide is anticipated to fuel the Roxadustat market’s expansion. CKD is a progressive condition in which the kidneys’ functionality deteriorates over time, potentially resulting in kidney failure if undiagnosed and untreated. The escalating numbers of CKD cases globally are attributable to aging populations, increased instances of diabetes and hypertension, and unhealthy lifestyles. Roxadustat aids in CKD management by promoting the production of erythropoietin which in turn boosts the production of red blood cells and helps tackle the anemia frequently linked with this disease, improving the overall renal function and patients’ quality of life. As an example, a December 2024 report from the Australian Institute of Health and Welfare (AIHW), a government agency based in Australia, indicated that the mortality rates from CKD saw a slight yearly increase, climbing by 4.2% in 2021 and 6.2% in 2022. Consequently, the increasing occurrence of chronic kidney disease (CKD) is fuelling the Roxadustat market’s growth._x000D_

_x000D_

#How Is the Roxadustat Market Segmented?#_x000D_

The roxadustat market covered in this report is segmented –_x000D_

_x000D_

1) By Type: 20mg, 50mg_x000D_

2) By Product Formulation: Oral Tablets_x000D_

3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers_x000D_

4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions_x000D_

_x000D_

Subsegments:_x000D_

1) By 20mg: Oral Tablets, Injectable Formulations_x000D_

2) By 50mg: Oral Tablets, Injectable Formulations_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21280&type=smp_x000D_

_x000D_

#Which Regions Are Driving the Next Phase of the Roxadustat Market Growth?#_x000D_

North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Key Market Trends and Innovations Are Shaping the Future of the Roxadustat Industry?#_x000D_

In the Roxadustat market, main players are opting to have their innovative treatments reimbursed under the high-tech drugs scheme. This move is intended to break down financial barriers and provide wider patient access, thereby spurring market growth and showcasing the cost-efficiency of these new therapies. Administered primarily in Ireland, the high-tech drugs scheme is a government-run program that facilitates reimbursement for the provision of costly, highly specialized medicines typically prescribed in hospital environments. An example of this was in September 2022 when Astellas Pharma Company Ltd., a pharmaceutical firm based in the US, announced that its drug EVRENZO (Roxadustat) had obtained reimbursement under Ireland’s High-Tech Drugs Scheme. Roxadustat, a novel class of oral hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitors, is the first of its kind to be licensed and reimbursed in Ireland. Studies revealed that Roxadustat effectively achieved and maintained target hemoglobin levels (10-12g/dL) in patients suffering from symptomatic anemia of CKD, independent of dialysis status and previous ESA treatment._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report_x000D_

_x000D_

#How Is the Roxadustat Market Defined and What Are Its Core Parameters?#_x000D_

Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stabilizes hypoxia-inducible factors, leading to increased erythropoietin production, enhanced iron absorption, and improved hemoglobin synthesis without the need for exogenous erythropoiesis-stimulating agents. It is used to manage anemia by addressing low hemoglobin levels in patients with chronic kidney disease and potentially other conditions involving impaired red blood cell production._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21280_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 3156230293_x000D_

Asia +44 2071930708_x000D_

Europe +44 2071930708_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the market grown in recent years?

In recent times, the Roxadustat market has experienced significant growth. Experts predict that it will expand from $6.44 billion in 2024 to $6.92 billion in 2025, registering a compound annual growth rate (CAGR) of 7.5%. The past growth is ascribed to regulatory clearance in crucial markets, impactful clinical trial outcomes, a rise in chronic kidney disease instances, boosted awareness about managing anemia, and government backing for anemia treatments.

How is the market size expected to evolve during the forecast period?

In the coming years, the Roxadustat market is anticipated to witness robust expansion. By 2029, it is projected to reach a staggering $9.16 billion, with a compound annual growth rate (CAGR) of 7.3%. The surge during this predictive cycle can be attributed to consistent research to uncover new applications, increased healthcare spending, acceleration of non-injectable anemia treatments, expansion of reimbursement policies, and a growing elderly population. The forecast period is expected to be characterized by trends such as a shift towards oral anemia treatments, intensifying competition from alternative treatments, broadening of licensing agreements, increasing funds in hypoxia-inducible factor research, and a concentration on providing patient-oriented treatment methods.

Get your market report here!

https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report

What main drivers are fueling expansion in the market?

The escalating prevalence of Chronic Kidney Disease (CKD) is anticipated to fuel the expansion of the Roxadustat market in the future. CKD, a chronic condition, gradually results in the loss of proper kidney function and can eventually lead to kidney failure if it is not appropriately addressed. As the global incidence of CKD climbs, a myriad of factors, including ageing populations, increased diabetes and hypertension rates, and unhealthy lifestyle choices, come to the fore. Roxadustat addresses CKD by spurring the production of erythropoietin, thus bolstering red blood cell productivity and mitigating the common occurrence of anemia related to the disease. This intervention results in an enhancement of overall kidney function and patient quality of life. Data from December 2024, in a report by the Australian Institute of Health and Welfare (AIHW), a government entity based in Australia, suggested a nominal annual increase in mortality rates due to CKD, with a 4.2% increase in 2021 and 6.2% rise in 2022. Consequently, the increasing population of individuals with CKD aids the Roxadustat market’s growth.

What are the market segments in the industry?

The roxadustat market covered in this report is segmented –

1) By Type: 20mg, 50mg

2) By Product Formulation: Oral Tablets

3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers

4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions

Subsegments:

1) By 20mg: Oral Tablets, Injectable Formulations

2) By 50mg: Oral Tablets, Injectable Formulations

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp

Which leading companies are shaping the growth of the market?

Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.

What key trends are currently impacting the market’s development?

Major corporations in the Roxadustat market are seeking reimbursement under the high-tech drugs scheme to expand patient reach by alleviating financial hurdles, thereby speeding up market absorption and proving their innovative treatments’ cost-efficiency. The high-tech drugs scheme is mainly a government-run program in Ireland that offers repayment for the administration of costly, highly specialized drugs usually prescribed in hospitals. For example, in September 2022, Astellas Pharma Company Ltd., a US-based pharmaceutical firm, revealed that its EVRENZO (Roxadustat) has received reimbursement under the High-Tech Drugs Scheme in Ireland. Roxadustat is the pioneer in a fresh class of orally taken hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitors licensed and reimbursed in Ireland. The findings indicated that Roxadustat was successful in reaching and maintaining target hemoglobin levels (10-12g/dL) in patients with symptomatic anemia of CKD, irrespective of dialysis status and prior ESA treatment.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21280

Which geographic areas are influencing the growth of the market?

North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Meningococcal Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Nontuberculous Mycobacterial Infection Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nontuberculous-mycobacterial-infection-global-market-report

Multidrug Resistant Bacteria Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/multidrug-resistant-bacteria-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Long-Term Projected Growth Rate for the Roxadustat Market, and What Are the Key Drivers?

In recent years, the market size of Roxadustat has seen considerable growth. The market, which amounts to $6.44 billion in 2024, is projected to expand to $6.92 billion in 2025, showing a compound annual growth rate (CAGR) of 7.5%. This growth during the historic period can be credited to regulatory clearances in key markets, impressive results from clinical trials, a rise in the number of chronic kidney disease cases, increased knowledge about anemia management, and governmental backing for anemia therapies.

In the ensuing years, the Roxadustat market is set to witness robust growth. It is anticipated to reach $9.16 billion by 2029, boasting a compound annual growth rate (CAGR) of 7.3%. The growth during this forecast period can be credited to ongoing investigations for novel indications, elevated healthcare expenses, a need for non-injectable anemia treatments, broadening reimbursement policies, and an aging global population. Key trends for the forecast period encompass a shift toward oral anemia therapies, intensified competition from alternative treatments, the proliferation of licensing agreements, increased funding for hypoxia-inducible factor research, and an emphasis on patient-focused treatment modalities.

How Are the key drivers Contributing to the Expansion of the Roxadustat Market?

The surge in the prevalence of chronic kidney disease (CKD) is anticipated to foster the expansion of the Roxadustat market. Chronic kidney disease (CKD) is a progressive condition, characterized by the steady loss of kidney functionality, eventually leading to kidney failure if neglected. The global spike in the number of people suffering from chronic kidney disease is attributed to an ageing population, escalating rates of ailments such as diabetes, hypertension and overall unhealthy living habits. Roxadustat assists in handling chronic kidney disease by promoting erythropoietin production, leading to an increase in the creation of red blood cells, tackling anemia often linked with the disease, thereby enhancing total kidney operation and life quality for those inflicted. For example, in December 2024, a report revealed by the Australian Institute of Health and Welfare (AIHW), a government agency based in Australia, showcased that mortality figures for chronic kidney disease witnessed a slight yearly increase, surging by 4.2% in 2021 and 6.2% in 2022. Hence, the escalating number of individuals afflicted with chronic kidney disease (CKD) is propelling the growth of the Roxadustat market.

Get Your Free Sample of the Global Roxadustat Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp

Which Companies Are Leading the Charge in Expanding the Roxadustat Market?

Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.

What New Trends Are Reshaping the Roxadustat Market and Its Opportunities?

Key businesses in the Roxadustat market are pursuing reimbursement through the high-tech drugs scheme, eliminating financial hindrances to expand patient accessibility, speeding up market absorption, and showcasing their innovative treatments’ cost-effectiveness. The high-tech drugs scheme is a government initiative predominantly in Ireland that offers financial coverage for the prescription of costly, highly specialized medicines often prescribed in hospitals. For example, in September 2022, Astellas Pharma Company Ltd., a U.S.-based pharmaceutical company, revealed that its EVRENZO (Roxadustat) had received reimbursement under Ireland’s High-Tech Drugs Scheme. Roxadustat represents the first of a new category of orally taken inhibitors called hypoxia-inducible factor prolyl hydroxylase (HIF PH), which have been licensed and reimbursed in Ireland. The reports reveal that Roxadustat successfully attained and maintained the target haemoglobin levels (10-12g/dL) in patients suffering from symptomatic anemia of CKD, regardless of their dialysis status and previous ESA treatment.

Get Instant Access to the Global Roxadustat Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report

What Major Market Segments Define the Scope and Growth of the Roxadustat Market?

The roxadustat market covered in this report is segmented –

1) By Type: 20mg, 50mg

2) By Product Formulation: Oral Tablets

3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers

4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions

Subsegments:

1) By 20mg: Oral Tablets, Injectable Formulations

2) By 50mg: Oral Tablets, Injectable Formulations

What Are the Top Regions Fueling Growth in the Roxadustat Market?

North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Roxadustat Market Defined Across Different Regions?

Roxadustat is an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stabilizes hypoxia-inducible factors, leading to increased erythropoietin production, enhanced iron absorption, and improved hemoglobin synthesis without the need for exogenous erythropoiesis-stimulating agents. It is used to manage anemia by addressing low hemoglobin levels in patients with chronic kidney disease and potentially other conditions involving impaired red blood cell production.

Browse Through More Similar Reports By The Business Research Company:

Meningococcal Vaccines Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Nontuberculous Mycobacterial Infection Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nontuberculous-mycobacterial-infection-global-market-report

Multidrug Resistant Bacteria Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/multidrug-resistant-bacteria-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: